<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar1584</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrin</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Auger</snm>
               <fnm>I</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Sebag</snm>
               <fnm>M</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Vincent</snm>
               <fnm>C</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>Guis</snm>
               <fnm>S</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Nogueira</snm>
               <fnm>L</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A6">
               <snm>Svensson</snm>
               <fnm>B</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A7">
               <snm>Cantagrel</snm>
               <fnm>A</fnm>
               <insr iid="I4"/>
            </au>
            <au id="A8">
               <snm>Serre</snm>
               <fnm>G</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A9">
               <snm>Roudier</snm>
               <fnm>J</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>INSERM UMR 639, Medical School and Rheumatology Ward, La Conception Hospital, Marseille, France</p>
            </ins>
            <ins id="I2">
               <p>CNRS-Toulouse III University UMR 5165, Purpan Hospital, Toulouse, France</p>
            </ins>
            <ins id="I3">
               <p>Rheumatology Ward, Helsingborg Lasarett AB, Helsingborg, Sweden</p>
            </ins>
            <ins id="I4">
               <p>Toulouse III University EA 2405 and Rheumatology Ward, Rangueil Hospital, Toulouse, France</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the meeting: Abbott Immunology (Main sponsor), Bristol-Myers Squibb, Schering-Plough, Wyeth, AstraZeneca, MSD, Amgen</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <location>Glasgow, UK</location>
            <date-range>24-27 February 2005</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 1</issue>
         <fpage>P63</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar1584</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>11</day>
               <month>1</month>
               <year>2005</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>17</day>
               <month>2</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2005</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>Rheumatoid arthritis (RA), a chronic inflammatory joint disease, develops in patients expressing particular HLA-DR alleles. RA patients' sera contain antibodies to a post-translationally modified form of fibrin on which arginyl residues are transformed in citrullins.</p>
         <p>We tested whether HLA-DR alleles influence the production of anti-citrullinated fibrin antibodies in RA patient sera and whether the replacement of arginyl residues by citrullyl residues on fibrin peptides could modify their binding to RA-associated HLA-DR molecules and their recognition by T cells in RA patients and controls.</p>
         <p>We found that RA-associated HLA-DR alleles are also associated with presence of anti-citrullinated fibrin antibodies in RA patient sera. Multiple peptides from the alpha and beta chain of fibrin are capable to bind many HLA-DR alleles. RA-associated HLA-DR alleles are good fibrin peptide binders. However, citrullination does not influence fibrin peptide binding to HLA-DR or fibrin peptide recognition by T cells.</p>
         <p>Finally, peripheral blood T cells that recognize native or citrullinated fibrin peptides are common in RA patients and very uncommon in normal controls.</p>
         <p>These results suggest that citrullination of fibrin has nothing to do with peptide/HLA-DR/T cell interaction and is merely involved in the definition of B-cell epitopes.</p>
      </sec>
   </bdy>
</art>
